Morgan Stanley reaffirmed an overweight recommendation and a $103 price objective on Monster Beverage Corp, arguing the energy drink maker’s broadest product innovation cycle on record is beginning to drive measurable gains in the U.S. The brokerage highlighted that items launched since late 2025 now represent about 14.5% of Monster’s U.S. scanner sales, a meaningful rise from virtually zero as of last September.
In premarket activity, Monster shares were up roughly 0.4% to $98, while Nasdaq 100 Futures rose about 0.2%.
The firm framed the current rollout as more expansive than prior efforts that largely emphasized flavor extensions. The latest pipeline spans multiple formats and concepts, including limited-time editions, shot-enhanced beverages, new brand introductions, and products adapted from successful concepts in European markets. Examples cited include the Ultra Red, White and Blue Razz limited-edition drink, Juice Monster Strawberry Lemonade, Strawberry Shots, the FLRT brand aimed at younger female consumers, the relaunch of Storm, plus U.S. introductions of Lando Norris Zero Sugar and Juice Monster Bad Apple.
Morgan Stanley said this broadened innovation approach should support near-term revenue growth and help establish groundwork for potential market-share gains over time. The brokerage noted the strategy may allow Monster to reach new consumers and sales channels while diminishing dependence on traditional flavor extensions. It further observed that many of the new items could be candidates for international rollout, which would matter given that foreign markets account for nearly half of Monster’s revenue mix.
The brokerage reported that recent launches have already begun to show up in improved U.S. market-share trends. Although Morgan Stanley continues to model modest share declines over a longer horizon, scanner data have shown year-over-year share gains in recent weeks, indicating the company’s innovation pipeline could deliver upside relative to current consensus expectations.
On the financial outlook, Morgan Stanley said it is keeping earnings projections above Wall Street consensus through 2028. The broker cited resilient global demand for energy drinks, ongoing international share gains, an anticipated margin recovery in 2027, and further operational improvements under management’s plan as the basis for its stance.
Overall, Morgan Stanley’s note portrays Monster’s current innovation cycle as the company’s strongest to date and a central element of its positive near- to medium-term thesis. The brokerage’s maintained rating and price target reflect the view that product variety and broadened distribution could support both sales and market-share momentum in the quarters ahead.
Summary
Morgan Stanley reiterated an overweight rating and a $103 price target on Monster Beverage, citing the strongest innovation cycle in the company’s history. Products launched since late 2025 now account for roughly 14.5% of U.S. scanner sales, and early signs point to improved U.S. share trends and support for above-consensus forecasts through 2028.